1. Fully Supporting Customer Needs for Biologics Development and Manufacturing

    James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.

  2. Focused on Fermentation

    Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.

  3. From Qualified to Ideal: The Importance of Partnership
    Nice Insight's virtual panelists weigh in on what makes contract service relationships work best.
  4. Nice Insight Overview: The Key to Pharma’s Next Generation Success

    Evolving markets are prompting drug owners and developers to pursue new business models in the post-blockbuster era.

  5. Supporting Parenteral Development and Manufacturing with End-to-End Services

    Oskar Gold, Senior Vice President of Key Account Management and Marketing/Corporate Communications for Vetter, explains leveraging end-to-end support.

  6. In Close Supplier-Partner Relationships, What Pitfalls Do You Try to Avoid? How Close is Too Close?

    Experts weigh in on our Roundtable question.

  7. FDA Approves New Migraine Treatment

    The first-in-class injectable, Aimovig, gains approval.

  8. New Single-Pill HIV Treatment Approved in Europe

    Juluca from ViiV Healthcare is the first 2-drug regimen offered in a once-daily pill.

  9. FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

    Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority.

  10. LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

    Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo. 

  11. Expanding U.S. Supply Options for Large-Volume Parenterals

    Marga Viñes, Business Development Manager, Grifols discusses the company’s vertical integration philosophy.

  12. Building the Foundation of Japan’s Premier CDMO

    Jun Yokohama, President & CEO of Bushu Pharmaceuticals Ltd. and Toshio Yoshioka, President at Spera Pharma, Inc. discuss how the firm helps clients overcome barriers to entry.

  13. Perspectives on Product Pricing Strategy and Practice
    Getting pricing “right” is a tricky balancing act, but one that offers tremendous value for all.
  14. Moving Beyond Monoclonal Antibodies
    Next-generation antibody therapeutics are designed to provide improved specificity, efficacy and safety when compared to conventional monoclonal antibodies.
  15. Becoming Bioavailable

    Poorly soluble molecules in the pipeline can have a negative effect on your active pharmaceutical ingredient (API).

  16. How is the Need to Provide Local Drug-Product Supply in Multiple Regions Around the World Impacting Pharmaceutical Manufacturing Facility and Equipment Design?
    Experts from across the industry lend their thoughts to the Roundtable.
  17. WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

    The new biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity.

  18. Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

    RETACRIT, the First U.S. Biosimilar Erythropoiesis-Stimulating Agent (ESA), is now approved across all indications.

  19. Cancer Immunotherapies Reach Patients More Quickly Than Other Drugs

    The rapid adoption of new cancer immunotherapies raises some concerns.

  20. Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins

    Engineered chemical trap detects rare glycoproteins emitted as cancer first develops.

Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.

New Single-Pill HIV Treatment Approved in Europe

May 22, 2018 1:53:45 PM PAO-M05-18-NI-015
FDA Approval

FDA Approves New Migraine Treatment

May 22, 2018 1:50:08 PM PAO-M05-18-NI-014

Cancer Immunotherapies Reach Patients More Quickly Than Other Drugs

May 18, 2018 11:48:11 AM PAO-M05-18-NI-013

Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins

May 18, 2018 11:43:59 AM PAO-M05-18-NI-012
Cell and Gene Therapy

Editas Founders Start New Gene Editing Company

May 17, 2018 12:40:28 PM PAO-M05-18-NI-011

Medigene, Bluebird Bio Collaboration on TCR Immunotherapy Extended

May 17, 2018 12:33:28 PM PAO-M05-18-NI-010
Used Equipment

With Expertise Comes Security

May 17, 2018 9:46:56 AM PA-M05-18-CL-001

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

May 15, 2018 11:30:45 AM PAO-M05-18-NI-009

Eli Lilly Makes Two Acquisitions in the Oncology Space

May 15, 2018 11:14:39 AM PAO-M05-18-NI-008

GlobalData Predicts Strong Sales for Humira Biosimilars in Europe

May 10, 2018 2:11:16 PM PAO-M05-18-NI-006

Nice Insight Overview

M&A Activity in a Fragmented CDMO Market
While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.


M&A: What Role has M&A Played in your Company’s Growth?

In Conversation

Operational Excellence in Outsourced Fill-Finish Services
Nice Insight is in conversation with Oskar Gold at Vetter Pharma International, a global leader in the fill-finish of aseptically prefilled syringe systems, cartridges and vials, about how outsourced supply of such services can help companies of all sizes.

In Conversation

M&A: Combining Market Segments

Dago Caceres and Gary Lord, The Dow Chemical Company